
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1551847
This article is part of the Research TopicChallenges in reaching the UNAIDS 95-95-95 targets in Sub-Saharan Africa: Status, innovations, and pathways forwardView all 8 articles
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The Joint United Nations Programme on HIV/AIDS set ambitious-but-reachable targets to have 95% of HIV-positive people diagnosed, 95% on ART, and 95% virally suppressed by 2030. To address the latter, post-2016, South Africa’s HIV treatment guidelines aimed to deliver maximal and durable viral load (VL) suppression through extensive antiretroviral therapy (ART) scale-up. Yet, standard suppression one-off measurement conceals viral response trajectories with high onward transmission potential for HIV patients on lifelong treatment. We investigated the dynamics of periodic VL patterns and associated socio-demographic factors in rural north-eastern South Africa using data from adults receiving HIV care in healthcare facilities within the Agincourt Health and Demographic Surveillance System (HDSS). We extracted two person-identified VL measurements collected 9-15 months apart per individual yearly between 2015 and 2020 from the Agincourt HDSS Hospital-Clinic-Linkage system for 7 493 HIV patients. Sankey diagrams were used to describe VL flows within and across the suppressed and unsuppressed statuses over each year. We classified temporal VL responses into four profiles: (i) Sustained suppression, (ii) achieved suppression, (iii) viral rebound, (iv) virologic failure. Additionally, mixed-effects multinomial logistic regression models were utilised to examine the odds of covariates factors for varied VL trajectories. The proportion of individuals remaining virally suppressed increased steadily from 84% in 2015 to 86% in 2016, with the highest prevalence of 88% sustained for three consecutive years, from 2017 through 2019, and then dropped slightly in 2020 to 87%. However, 2-3% of initially virally suppressed rebounded annually, while ~5% experience treatment failure. The likelihood of achieving viral suppression was high among men, those aged 15-24 years and 25-34 years however, these groups were less likely to have sustained viral suppression and more likely to experience virologic failure and rebounding. Temporal VL metrics are needed to effectively track progress towards reaching high and sustained HIV suppression potential in HIV hyperendemic settings. Thus, optimising the assessment of targeted interventions and identification of left-behind groups such as those younger, men, unmarried and poorer HIV patients to improve individual and population health outcomes.
Keywords: Sustained viral suppression, Treatment Failure, Viral rebound, Viral response, antiretroviral therapy, hiv/aids
Received: 26 Dec 2024; Accepted: 10 Apr 2025.
Copyright: © 2025 Dzomba, GOMEZ-OLIVE, Bashingwa, Sibanda, Njiro, Kahn, Ohene-Kwofie and Kabudula. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Armstrong Dzomba, Medical Research Council/Wits Rural Public Health and Health Transitions Research Unit, Johannesburg, South Africa
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.